Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Multiple Sclerosis, Chronic Progressive

• Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
• A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
• Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration
• Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis
• Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
• Novel Imaging Markers in SPMS
• Metformin Treatment in Progressive Multiple Sclerosis
• A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In
• Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis
• Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
• Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS
• Hydroxychloroquine and Indapamide in SPMS
• Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis
• Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)
• Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis
• ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis
• Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis
• Novel Assessment of Synaptic Density in Progressive MS
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
• A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis
• Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)
• Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)
• Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS).
• Phase II Clinical Trial of OCH-NCNP1
• A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
• Simvastatin in Secondary Progressive Multiple Sclerosis
• SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis
• Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714
• Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP)
• A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)
• A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis
• Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis
• A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis
• Multiple Sclerosis-Simvastatin Trial 2
• Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS
• Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients
• Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
• Neural Stem Cell Transplantation in Multiple Sclerosis Patients
• Lipoic Acid for Progressive Multiple Sclerosis (MS)
• Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis
• A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
• Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis
• Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
• Hydroxychloroquine in Primary Progressive Multiple Sclerosis
• Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)
• Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
• A Study of Oxidative Pathways in MS Fatigue
• Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)
• Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers
• Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study
• A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis
• Intrathecal Rituximab in Progressive Multiple Sclerosis
• Open-label Study of Liothyronine in MS
• Autologous Mesenchymal Stromal Cells for Multiple Sclerosis
• BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis
• Domperidone in Secondary Progressive Multiple Sclerosis (SPMS)
• Imaging of Intracerebral Inflammation in MS
• Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis
• A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
• A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
• Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS
• A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients
• Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis
• Effect of MD1003 in Spinal Progressive Multiple Sclerosis
• A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MS
• Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
• ACTH in Progressive Forms of MS
• A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis
• MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial
• Idebenone for Primary Progressive Multiple Sclerosis
• Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis
• Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
• Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
• Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis
• China Betaferon Adherence, Coping and Nurse Support Study
• Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis
• A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
• Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis
• A Pilot Study of Lithium in Progressive Multiple Sclerosis
• Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors
• AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis
• Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
• A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
• Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)
• The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple Sclerosis
• Hydroxyurea in Primary Progressive Multiple Sclerosis
• Natalizumab Treatment of Progressive Multiple Sclerosis
• Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)
• A Study for Patients With Multiple Sclerosis
• A Study for Patients With Secondary Progressive Multiple Sclerosis
• Sunphenon in Progressive Forms of Multiple Sclerosis
• This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.
• Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis
• Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
• Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis
• Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With MS
• Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis
• Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)
• A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis
• Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis
• Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients
• Study Evaluating Mitoxantrone in Multiple Sclerosis
• A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis